Renal Denervation Devices Market by Technology (Micro-Infusion-Based, Pharmacologic Ablation, Radiofrequency-Based), Products (Catheters, Nerve Modifying Agents, RF Generator), Disease Application, End-User - Global Forecast 2024-2030
The Renal Denervation Devices Market size was estimated at USD 236.29 million in 2023 and expected to reach USD 266.44 million in 2024, at a CAGR 13.68% to reach USD 579.85 million by 2030.
Renal denervation devices are medical tools that provide minimally invasive therapy for patients suffering from drug-resistant hypertension or high blood pressure that do not respond adequately to conventional pharmacological therapies. These devices offer an alternative solution by targeting the overactive sympathetic nerves surrounding the renal arteries, which play a crucial role in regulating blood pressure and contribute to the development of hypertension. The increasing prevalence of resistant hypertension among the global population due to lifestyle changes, rising awareness about the benefits of renal denervation procedures over conventional drug therapies, and the growing geriatric population are driving the renal denervation devices market growth. However, the high cost of renal denervation devices, associated procedures, and several stringent regulatory frameworks may hamper market growth. Technological advancements in device design and procedural techniques have improved efficacy and safety profiles for renal denervation treatments, which is expected to create a lucrative market opportunity.
Regional Insights
The Americas has a significant landscape in the renal denervation devices market due to a high prevalence of hypertension among its population and substantial investments in research for novel therapies. Advancements in technology and growing awareness about innovative treatment options amongst healthcare professionals have fueled demand for these devices. The EU shows significant potential for market growth owing to increased awareness about renal denervation therapy and favorable reimbursement policies across countries. Collaborative efforts on hypertension prevention and control have accelerated R&D initiatives in this domain. The MEA region holds promising opportunities for renal denervation devices due to a rising incidence of hypertension coupled with lifestyle changes and urbanization. In the APAC region, government funding and initiatives for hypertension research resulted in a growing number of clinical trials and patent filings. Robust healthcare infrastructure, a strong focus on technological advancements, increased awareness about hypertension management, and improved healthcare facilities have contributed to the region's renal denervation devices market growth.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Renal Denervation Devices Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rising prevalence of congestive chronic renal failure with aging population
- Growing adoption and inclination towards minimally invasive surgical procedures
- Market Restraints
- High cost associated with renal denervation devices
- Market Opportunities
- Technological advancements and improvements in renal denervation devices
- Ongoing publishing of clinical guidelines for renal denervation and increasing clinical assessment studies
- Market Challenges
- Strict government regulations for product approval coupled with lack of experienced healthcare professionals
- Market Segmentation Analysis
- Technology: High adoption of ultrasound-based renal denervation technology
- Product: Significant use of multi-electrode catheters for their shorter-time of procedures
- Disease Application: Proliferating use of renal denervation devices for treating hypertension
- End-User: Ambulatory care centers prioritize renal denervation devices as a minimally invasive and cost-effective solution
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Renal Denervation Devices Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Renal Denervation Devices Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Recor Medical, Inc. and Otsuka Medical Devices Co., Ltd., its parent company, have announced the FDA approval of their Paradise Ultrasound Renal Denervation System for the treatment of hypertension. The Paradise System is designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, thus reducing hypertensive overactivity.
FDA Approves Verve Medical’s IDE Renal Pelvic Denervation Trial
Verve Medical, Inc. has received an Investigational Device Exemption from the U.S. Food and Drug Administration ( FDA) for its renal denervation trial. The trial aims to estimate the safety and efficacy of the procedure by testing 300 patients. This pivotal trial by Verve is a 2:1 randomized, double-blinded, sham-controlled study, and it has the potential to benefit over 1 billion people worldwide who suffer from uncontrolled hypertension.
Korean Startup Kalos Gets USD 3.5 Million Grant to Develop Renal Denervation Device for hypertension Treatment
Kalos Medical received a grant of KRW 4.67 billion (approximately USD 3.5 million) to expedite the development of its renal denervation medical device and to participate in the 2023 Industrial Technology Innovation Project. This project aims to combine MNTek's biomedical sensor technology with KETI's electronic medical device control system to enhance the development of Kalos' renal denervation medical device.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Renal Denervation Devices Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Renal Denervation Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ablative Solutions, Inc., AngioDynamics, Inc., Aria CV, Inc., AtriCure, Inc., Bio-Heart, Boston Scientific Corporation, Cardinal Health, Inc., Kalos Medical, Medtronic PLC, Mercator MedSystems, Inc., Otsuka Holdings Co., Ltd., Shanghai Meiliweiye Medical Technology Co., Ltd., SoniVie, Symap Medical, Ltd., Symple Surgical, Inc., and Terumo Corporation.
Market Segmentation & Coverage
This research report categorizes the Renal Denervation Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:- Technology
- Micro-Infusion-Based
- Pharmacologic Ablation
- Radiofrequency-Based
- Ultrasound-Based
- Products
- Catheters
- Multi Electrode Catheter
- Single Electrode Catheter
- Nerve Modifying Agents
- RF Generator
- Disease Application
- Diabetes
- Heart Failure
- Hypertension
- Renal Failure
- End-User
- Ambulatory Care Centers
- Diagnostic Centers & Hospitals
- Research & Academia
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Catheters
- Market Drivers
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of congestive chronic renal failure with aging population
- 5.1.1.2. Growing adoption and inclination towards minimally invasive surgical procedures
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with renal denervation devices
- 5.1.3. Opportunities
- 5.1.3.1. Technological advancements and improvements in renal denervation devices
- 5.1.3.2. Ongoing publishing of clinical guidelines for renal denervation and increasing clinical assessment studies
- 5.1.4. Challenges
- 5.1.4.1. Strict government regulations for product approval coupled with lack of experienced healthcare professionals
- 5.2. Market Segmentation Analysis
- 5.2.1. Technology: High adoption of ultrasound-based renal denervation technology
- 5.2.2. Product: Significant use of multi-electrode catheters for their shorter-time of procedures
- 5.2.3. Disease Application: Proliferating use of renal denervation devices for treating hypertension
- 5.2.4. End-User: Ambulatory care centers prioritize renal denervation devices as a minimally invasive and cost-effective solution
- 5.3. Market Trend Analysis
- 5.3.1. Favorable government approvals for renal denervation devices in the Americas backed by the presence of well-established medical device companies and rising medical professional acceptance
- 5.3.2. Expanding government support to improve diagnosis and treatment of hypertension coupled with increasing positive results from clinical trials of renal denervation devices in the APAC region
- 5.3.3. Supportive government initiatives and approval procedures for renal denervation devices across the EMEA region
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Renal Denervation Devices Market, by Technology
- 6.1. Introduction
- 6.2. Micro-Infusion-Based
- 6.3. Pharmacologic Ablation
- 6.4. Radiofrequency-Based
- 6.5. Ultrasound-Based
- 7. Renal Denervation Devices Market, by Products
- 7.1. Introduction
- 7.2. Catheters
- 7.3. Nerve Modifying Agents
- 7.4. RF Generator
- 8. Renal Denervation Devices Market, by Disease Application
- 8.1. Introduction
- 8.2. Diabetes
- 8.3. Heart Failure
- 8.4. Hypertension
- 8.5. Renal Failure
- 9. Renal Denervation Devices Market, by End-User
- 9.1. Introduction
- 9.2. Ambulatory Care Centers
- 9.3. Diagnostic Centers & Hospitals
- 9.4. Research & Academia
- 10. Americas Renal Denervation Devices Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Renal Denervation Devices Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Renal Denervation Devices Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
- 13.3.2. FDA Approves Verve Medical’s IDE Renal Pelvic Denervation Trial
- 13.3.3. Korean Startup Kalos Gets USD 3.5 Million Grant to Develop Renal Denervation Device for hypertension Treatment
- 13.3.4. Renal Denervation Using Ultrasound Ablation in Treatment-Resistant Hypertension is Being Evaluated for Early Benefit Assessment in Germany
- 13.3.5. Andera Partners Invests in SoniVie, a Medtech Company Developing a Promising Device for the Treatment of Hypertension
- 13.3.6. Transitional Coverage for Renal Denervation Catheter SYMPLICITY SPYRAL from Medtronic in France
- 13.3.7. Shanghai Golden Leaf Med Tec Co., Ltd Secures Hundreds of Mns of CNY in Series C Round
- 13.3.8. SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with other SPYRAL HTN Renal Denervation Trials
- 13.3.9. SoniVie Receives IDE Approval from FDA for its Pilot Study to Treat Hypertension with its Renal Artery Denervation TIVUS Technology
- 13.3.10. Ablative Solutions Raises USD 91.4 Million in Series D Financing Round
- 13.3.11. Clinical Accelerator Announces Collaboration with Verve Medical to Conduct an Early Human Feasibility Study for Treatment-Resistant Hypertension
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook